AEON Biopharma Announces Director & Officer Changes
Ticker: AEON · Form: 8-K · Filed: Apr 21, 2025 · CIK: 1837607
Sentiment: neutral
Topics: governance, executive-compensation, board-changes
TL;DR
AEON Biopharma shakes up its board and exec pay structure.
AI Summary
AEON Biopharma, Inc. announced on April 19, 2025, changes related to its board of directors and executive compensation. The filing details the departure of certain officers and directors, the election of new directors, and adjustments to compensatory arrangements for key personnel.
Why It Matters
Changes in a company's board and executive compensation can signal shifts in strategy, governance, or financial outlook, impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in board composition and executive compensation can indicate internal shifts that may affect the company's future direction and stability.
Key Players & Entities
- AEON Biopharma, Inc. (company) — Registrant
- Priveterra Acquisition Corp. (company) — Former Company Name
FAQ
What specific roles have been affected by the director and officer changes?
The filing indicates changes in the roles of directors and certain officers, though specific names and exact role changes are detailed within the document's exhibits.
When were these changes effective?
The earliest event reported in this 8-K filing was on April 19, 2025.
What is AEON Biopharma's primary business?
AEON Biopharma, Inc. is in the Pharmaceutical Preparations industry, SIC code 2834.
Where is AEON Biopharma headquartered?
AEON Biopharma, Inc. is headquartered at 5 Park Plaza, Suite 1750, Irvine, CA 92614.
What was AEON Biopharma's former name?
AEON Biopharma, Inc. was formerly known as Priveterra Acquisition Corp. before a name change on December 22, 2020.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 21, 2025 regarding AEON Biopharma, Inc. (AEON).